Benzodiazepines in the treatment of premenstrual and menopausal syndromes

Tikhomirov A.L., Sarsania S.I., Tuskaev K.S., Kazenashev V.V., Manukhin I.B.

1A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow 127473, Delegatskaya str. 20, bld. 1, Russia 2Federal Center for reproduction “Santa Maria”, Moscow 127051, Tsvetnoy Boulevard str. 25, bld. 5, Russia
Objective. To provide an update-based assessment of the relationship between genetic disorders of the receptor system and somatic and autonomic dysfunctions developing in the framework of premenstrual syndrome and premenstrual dysphoric disorder. The results of new trials of the efficacy of tofisopam (grandaxin) were also analyzed.
Material and methods. Publications available in the international science citation databases were sought and analyzed.
Results. Tofisopam (grandaxin) is an anxiolytic drug but without muscle relaxant effects; and it can therefore be used in patients who continue to perform their professional duties. Tofisopam has the greatest autonomic stabilizing effect. Tofisopam has been shown to be particularly effective against autonomic disorders accompanying anxiety.
Conclusion. Tofisopam remains one of the best drugs in the safety and efficacy ratio today.

Keywords

premenstrual syndrome
premenstrual dysphoric disorder
depressive syndrome in pregnant women
postpartum depressions
climacteric and postovariectomic syndrome
daytime anxiolytic grandaxin

References

1. Reid R.L., Case A.M. Premenstrual syndrome and menstrual-related disorders. In: Facone T, Hurd WW., eds. Clinical reproductive medicine and surgery. Philadelphia (PA): Mosby Elsevier; 2007: 335.

2. Torchinov A.M., Bardenshtein L.M., Polukhova E.V., Firichenko V.I. Premenstrual syndrome (issues of pathogenesis, clinical picture and treatment). Ginekologiya. 2010; 12 (2): 21-5. (in Russian)

3. American College of Obstetricians and Gynecologists: ACOG Practice Bulletin, Clinical Management Guidelines for Obstetrician-Gynecologists, N 15. „Premenstrual Syndrome”. Washington, DC: ACOG; 2000; N 95: 1-9.

4. Prilepskaya V.N., Mezhevitinova E.A. Premenstrual syndrome. Ginekologiya. 2005; 7 (4): 210-4. (in Russian)

5. Braverman P.K. Mini-review premenstrual syndrome and premenstrual dysphoric disorder. J. Pediatr. Adolesc. Gynecol. 2007; 20: 3-12.

6. Ismail K.M.K., O’Brien S. Premenstrual syndrome. Curr. Obstet. Gynecol. 2001; 2: 251-5.

7. Ismail K.M.K., O’Brien S. Premenstrual syndrome. Curr. Obstet. Gynecol. 2005; 15: 25-30.

8. Indusekhar R., Usman S.B., O’Brien S. Psychological aspects of premenstrual syndrome. Best Pract. Res. Clin. Obstet. Gynaecol. 2007; 21: 207-20.

9. Ozgii O., Defne E., Hayriye E.M., Serdar O. The risk factors and symtomatology of perimenopausal depression. Maturitas. 2006; 55(2): 180-6.

10. Grady-Weliky T.A. Premenstrual dysphoric disorder. N Engl J Med. 2003; 348(5): 433-8.

11. Wayne A.M., ed. Vegetative disorders: clinic, diagnosis, treatment. Moscow: MIA; 2000.752p. (in Russian)

12. Tatarchuk T.F., Ventskovsky I.B., Shevchuk Т.V. Modern view on the mechanisms of development, diagnosis and treatment of premenstrual disorders. International Endocrinology Journal/Mezhdunarodnyiy endokrinologicheskiy zhurnal. 2007; 1(7). (in Russian)

13. Kuhl H. New gestagens – advantages and disadvantages. Ther. Umsch. 2005; 58(9): 527-33.

14. Derman O., Kanbur N.O., Tokur T.E., Kutluk T. Premenstrual syndrome and associated symptoms in adolescent girls. Eur. J. Obstet. Gynecol. Reprod. Biol. 2004; 116(2): 201-6.

15. Vichnin M., Freeman E. W., Lin H., Hillman J., Bui S. Premenstrual Syndrome (PMS) in adolescents: severity and impairment. J. Pediatr. Adolesc. Gynecol. 2006; 19: 397-402.

16. Campagne D.M., Campagne G. The premenstrual syndrome revisited. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007; 130: 4-17.

17. Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder-clinical procedures and research perspectives. Gynecol. Endocrinol. 2004; 19: 320-34.

18. Tyvina N.A. The importance of premenstrual syndrome for early diagnosis, prognosis and prevention of mental illness in women. In: Scientific Research and the Problems of Teaching in Psychiatry. Moscow; 1987: 52-4. (in Russian)

19. Dubey N., Hoffman J.F., Schuebel K., Yuan Q., Martinez P.E., Nieman L.K. et al. The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. Mol. Psychiatry. 2017; Jan 3.

20. Kuznetsova I.V., Konovalov V.A. Modern therapy of premenstrual syndrome (review of literature). Ginekologiya. 2013; 15(3): 20-5. (in Russian)

21. Dyukova G.M. Grandaxin in clinical practice. Lechenie nervnyih bolezney. 2005; 2: 25-9. (in Russian)

22. Ronai Sh., Oros F., Bolla K. The use of grandaxin in outpatient practice. Vengerskaya farmakoterapiya. 1975; 23: 4-10. (in Russian)

23. Szegi J., Somogyi M., Papp E. Excerpts from the clinical-pharmacologic and clinical studies of Grandaxin. Acta Pharm. Hung. 1993; 63(2): 91-8.

24. Saano V., Tacke U., Sopanen L., Airaksinen M.M. Tofizopam enhances the action of diazepam against tremor and convulsions. Med. Biol. 1983; 61(1): 49-53.

25. Saano V. Tofizopam selectively increases the action of anticonvulsants. Med. Biol. 1986; 64(4): 201-6.

26. Horváth E.J., Horváth K., Hámori T., Fekete M.I., Sólyom S., Palkovits M. Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia. Prog. Neurobiol. 2000; 60(4): 309-42.

27. Chopin P., Stenger A., Couzinier J.P. Briley M. Indirect dopaminergic effects of tofisopam, a 2,3-benzodiazepine, and their inhibition by lithium. J. Pharm. Pharmacol. 1985; 37(12): 917-9.

28. Petócz L. Pharmacologic effects of tofizopam (Grandaxin). Acta Pharm. Hung. 1993; 63(2): 79-82.

29. Hovi-Viander M., Kanto J. Tofisopam and midazolam: differences in clinical effects and in changes of CSF monoamine metabolites. Br. J. Clin. Pharmacol.1985; 20: 492-6.

30. Bernard P., Dufresne-Favetta C., Favetta P., Do Q.-T., Himbert F., Zubrzycki S., Scior T. Application of drug repositioning strategy to TOFISOPAM. Curr. Med. Chem. 2008; 15: 3196-203.

31. Kalashnikov S.V., Kalashnikova E.A., Kokarovtseva S.N. Immunomodulating effects of tofizopam (Grandaxin) and diazepam in vitro. Mediators Inflamm. 2002; 11: 53-9.

32. Bond Б., Lader М. A comparison of the psychotropic proffles of tofisopam and diazepam. Eur. J. Clin. Pharmacol. 1982; 22(2): 137-42.

33. Kanto J., Kangas L., Leppnen Ф, Mansikka М, Sibakov M.L. Toftzopam: a benzodiazepine derivative without sedative effect. Int. J. Clin. Pharmacol. Ther. Toxicol. 1982; 20(7): 309-12.

34. Pakkanen Б., Kanto J., Kangas L., Mansikka М. Comparative study of the clinical effects of tofizopam, nitrazepam and placebo as oral premedication. Br. J. Anaesth. 1980; 52(10): 1009-12.

35. Sepp T., Palva E., Manila M.J., Korttila K., Shrotriya R.C. Tofisopam, a novel 3,4-benzodiazepine: multiple-dose effects on psychomotor skills and memory- Comparison with diazepam and interactions with ethanol. Psychopharmacology(Berlin). 1980; 69(2): 209-18.

36. Mashkovskiy M.D. Medicinal products. 15-e izd. Moscow: Novaya Volna; 2006. 1206p. (in Russian)

37. Soloveva A.D., Buyachinskaya A.I. Grandaxin in the treatment of premenstrual syndrome. Lechenie nervnyih bolezney. 2001; 2(3): 29-31. (in Russian)

38. Artemenko A.R., Oknin V.Yu. Grandaxin in the treatment of psycho-vegetative disorders. Lechenie nervnyih bolezney. 2001; 2(1): 24-7. (in Russian)

39. Smetnik V.P., Tumilovich L.G. Non-surgical gynecology. Moscow: MIA; 2001: 104, 241. (in Russian)

40. Strizhakov A.N., Podzolkova N.M., Glazkova O.L., Romanova E.N. Grandaxin as a possible alternative to hormone replacement therapy. Bulletin of the Russian Association of Obstetricians and Gynecologists. 2000; 3: 67-9. (in Russian)

41. Kabaev R.S., Abramchenko V.V., Kulichkin Yu.V. et al. Evaluation of the effectiveness of benzodiazepine derivatives (diazepam, grandaxin) in the provision of drug sleep-rest and regulation of labor. Zhurnal akusherstva i zhenskih bolezney. 2002; 51(1): 12-6. (in Russian)

Received 21.04.2017

Accepted 28.04.2017

About the Authors

Tikhomirov Alexander Leonidovich, Doctor of Medical Sciences, Professor of the Department of Obstetrics and Gynecology, Faculty of General Medicine, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia.
127473, Russia, Moscow, Delegatskaya str. 20, bld. 1. Tel.: +74951782831. Email: pacificoff@mail.ru
Sarsania Svetlana Inorovna, doctor of the Federal Center for reproduction „Santa Maria”. 127051, Russia, Moscow, Tsvetnoy Boulevard str. 25, bld. 5. Tel.: +74959898981
Tuskaev Kazbek Serafilovich, doctor of the Federal Center for reproduction “Santa Maria”. 127051, Russia, Moscow, Tsvetnoy Boulevard str. 25, bld. 5. Tel.: +74959898981
Kazenashev Viktor Viktorovich, Candidate of Medical Sciences, Assistant of the Department of Obstetrics and Gynecology, Faculty of General Medicine,
A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia. 127473, Russia, Moscow, Delegatskaya str. 20, bld. 1. Tel.: +74951782831
Manukhin Igor Borisovich, MD, Professor, Head of the Department of Obstetrics and Gynecology, Faculty of General Medicine, A.I. Yevdokimov
Moscow State University of Medicine and Dentistry, Ministry of Health of Russia. 127473, Russia, Moscow, Delegatskaya str. 20, bld. 1. Tel.: +74991782831

For citations: Tikhomirov A.L., Sarsania S.I., Tuskaev K.S., Kazenashev V.V., Manukhin I.B. Benzodiazepines in the treatment of premenstrual and menopausal syndromes.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (5): 132-7. (in Russian)
http://dx.doi.org/10.18565/aig.2017.5.132-7

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.